返回 Agenda
[Session 3]Cardiovascular risk assessment of antitumor drugs
Session Chair(s)
Keita Fujikawa
Head of General Medicine, Japan Medical Office
Takeda Pharmaceutical Company Limited, Japan
Yuji Kumagai, MD, PHD
Professor, Kitasato Clinical Research Center
Kitasato University Hospital, Japan
Speaker(s)
Safety translational research for cardio-oncology using iPS cells
Tadahiro Shinozawa, PHD
Takeda Pharmaceutical Company Limited, Japan
Associate Director, Drug Safety Research Lab, Regenerative Medicine Unit
Development of preventive treatment against anticancer drug-induced side effects using big data analysis
Yoshito Zamami
Tokushima University Graduate School, Japan
Associate professor, Department of Clinical Pharmacology and Therapeutics,
Cardiovascular risk assessment of antitumor drugs
Hideaki Takahashi
Pharmacheuticals and Medical Devices Agency, Japan
Reviewer